Prednisone
- Generic Name
- Prednisone
- Brand Names
- Deltasone, Rayos, Winpred
- Drug Type
- Small Molecule
- Chemical Formula
- C21H26O5
- CAS Number
- 53-03-2
- Unique Ingredient Identifier
- VB0R961HZT
- Background
A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.
Prednisone was granted FDA approval on 21 February 1955.
- Indication
Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.
- Associated Conditions
- Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis
- Associated Therapies
- Palliative Treatment
PII Trial of Docetaxel/Prednisone w/Sargramostim for HRPC
- Conditions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2012-05-11
- Lead Sponsor
- Veeda Oncology
- Target Recruit Count
- 35
- Registration Number
- NCT00313482
- Locations
- 🇺🇸
Veeda Oncology, Columbus, Ohio, United States
Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
- Conditions
- Interventions
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2013-04-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 204
- Registration Number
- NCT00313781
- Locations
- 🇬🇧
Pfizer Investigational Site, Guildford, United Kingdom
Study Comparing Effect On Carotid Atherosclerosis Following Conversion From Tacrolimus To Sirolimus Post-Transplant In Kidney Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2006-04-05
- Last Posted Date
- 2013-09-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 72
- Registration Number
- NCT00311311
- Locations
- 🇨🇦
Pfizer Investigational Site, Montreal, Quebec, Canada
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT)
- Conditions
- First Posted Date
- 2006-04-03
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- German CLL Study Group
- Target Recruit Count
- 75
- Registration Number
- NCT00309881
- Locations
- 🇩🇪
Kreiskrankenhaus, Bad Hersfeld, Germany
🇩🇪Internistische Onkologische Praxis - Kronach, Kronach, Germany
🇩🇪Universitaetsklinikum Essen, Essen, Germany
CoQ10 and Prednisone in Non-Ambulatory DMD
- Conditions
- Interventions
- First Posted Date
- 2006-03-29
- Last Posted Date
- 2013-11-08
- Target Recruit Count
- 3
- Registration Number
- NCT00308113
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Trial of Rituximab Versus Oral Cyclophosphamide to Eradicate or Suppress Autoimmune Anti-Factor VIII Antibodies in Acquired Hemophilia A
- First Posted Date
- 2006-03-24
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 2
- Registration Number
- NCT00306670
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-03-17
- Last Posted Date
- 2013-08-14
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 5
- Registration Number
- NCT00304018
- Locations
- 🇺🇸
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2021-03-30
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 287
- Registration Number
- NCT00302003
- Locations
- 🇺🇸
Children's Oncology Group, Arcadia, California, United States
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-03-13
- Last Posted Date
- 2019-10-09
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 107
- Registration Number
- NCT00301821
- Locations
- 🇺🇸
Mason District Hospital, Havana, Illinois, United States
🇺🇸Perry Memorial Hospital, Princeton, Illinois, United States
🇺🇸Carle Cancer Center at Carle Foundation Hospital, Urbana, Illinois, United States
Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2006-02-24
- Last Posted Date
- 2018-11-20
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 79
- Registration Number
- NCT00295932
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center @ Suffolk, Commack, New York, United States
🇺🇸Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School, New Brunswick, New Jersey, United States
🇺🇸Memorial Sloan-Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.